Active Ingredient History
Radium Ra 223 dichloride is a radiotherapeutic drug that is approved for the treatment of male patients with symptoms of advanced prostate cancer with bone metastases. Ra 223 mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover. The radioactive alpha particles emitted by radium Ra 223 helps in killing cancer cells in the bone by damaging their DNA. Radium Ra 223 causes minimal damage to the nearby healthy cells. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Prostatic Neoplasms, Castration-Resistant (approved 2013)
Bone Diseases (Phase 1)
Breast Neoplasms (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 1/Phase 2)
Carcinoma, Transitional Cell (Early Phase 1)
Multiple Myeloma (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 1)
Pain (Phase 2)
Pharmacokinetics (Phase 1)
Prostatic Neoplasms (Phase 3)
Sarcoma (Phase 1/Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Thyroid Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue